NasdaqGM:HROWPharmaceuticals
Assessing Harrow (HROW) Valuation As Heavy Insider Selling Tests The Undervaluation Story
Insider selling puts Harrow (HROW) under the microscope
Heavy insider selling at Harrow (HROW) has caught investor attention after company insiders sold about US$8.1 million of stock over the past 3 months, with no reported insider purchases.
This activity comes as Harrow shares recently fell 3.6% to US$35.93. At the same time, external models such as GuruFocus’s GF Value suggest the stock may be modestly undervalued, creating a tension between insider behavior and valuation signals.
See our...